Literature DB >> 25580142

Bilateral Ovarian Metastases from ALK Rearranged Non-Small Cell Lung Cancer.

Kyung Ann Lee1, Jong Sik Lee1, Jae Ki Min1, Hee Joung Kim1, Wan Seop Kim2, Kye Young Lee1.   

Abstract

Anaplastic lymphoma kinase (ALK) rearrangement, is a kind of driver mutation, accounts for 3%-5% of non-small cell lung cancer (NSCLC). NSCLC patients harboring ALK fusion genes have distinct clinical features and good response to ALK inhibitors. Metastasis from lung cancer to the ovary has rarely been known. We report a case of a 54-year-old woman with bilateral ovarian metastases from ALK rearranged NSCLC. She underwent bilateral salpingo-oophorectomy for ovary masses, which were progressed after cytotoxic chemotherapy although primary lung mass was decreased. Histopathological examination of the ovary tumor showed characteristic adenocarcinoma patterns of the lung and ALK rearrangement.

Entities:  

Keywords:  Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Ovary

Year:  2014        PMID: 25580142      PMCID: PMC4286783          DOI: 10.4046/trd.2014.77.6.258

Source DB:  PubMed          Journal:  Tuberc Respir Dis (Seoul)        ISSN: 1738-3536


  12 in total

1.  Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.

Authors:  Robert C Doebele; Xian Lu; Christopher Sumey; Delee A Maxson; Andrew J Weickhardt; Ana B Oton; Paul A Bunn; Anna E Barón; Wilbur A Franklin; Dara L Aisner; Marileila Varella-Garcia; D Ross Camidge
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

2.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

3.  Cystic brain metastasis in non-small-cell lung cancer with ALK rearrangement.

Authors:  Hidetoshi Hayashi; Isamu Okamoto; Junko Tanizaki; Kaoru Tanaka; Takeshi Okuda; Amami Kato; Yasumasa Nishimura; Kazuhiko Nakagawa
Journal:  J Clin Oncol       Date:  2014-02-24       Impact factor: 44.544

4.  Lung carcinoma metastatic to the ovary: a clinicopathologic study of 32 cases emphasizing their morphologic spectrum and problems in differential diagnosis.

Authors:  Julie A Irving; Robert H Young
Journal:  Am J Surg Pathol       Date:  2005-08       Impact factor: 6.394

5.  Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma.

Authors:  Ping Yang; Kimary Kulig; Jennifer M Boland; Michele R Erickson-Johnson; Andre M Oliveira; Jason Wampfler; Aminah Jatoi; Claude Deschamps; Randolph Marks; Connie Fortner; Shawn Stoddard; Francis Nichols; Julian Molina; Marie-Christine Aubry; Hui Tang; Eunhee S Yi
Journal:  J Thorac Oncol       Date:  2012-01       Impact factor: 15.609

Review 6.  The biology and treatment of EML4-ALK non-small cell lung cancer.

Authors:  Takaaki Sasaki; Scott J Rodig; Lucian R Chirieac; Pasi A Jänne
Journal:  Eur J Cancer       Date:  2010-04-24       Impact factor: 9.162

7.  Ovarian metastasis from pulmonary adenocarcinoma.

Authors:  Young-Eun Jung; Jeong-Won Lee; Byoung-Gie Kim; Duk-Soo Bae
Journal:  Obstet Gynecol Sci       Date:  2013-09-14

8.  Metastatic ovarian tumors: a clinicopathologic study of 150 cases.

Authors:  Isabel Alvarado-Cabrero; Adriana Rodríguez-Gómez; Jorge Castelan-Pedraza; Raquel Valencia-Cedillo
Journal:  Anal Quant Cytopathol Histpathol       Date:  2013-10

9.  Clinical implications of metastases to the ovary.

Authors:  K Fujiwara; Y Ohishi; H Koike; S Sawada; T Moriya; I Kohno
Journal:  Gynecol Oncol       Date:  1995-10       Impact factor: 5.482

10.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

View more
  7 in total

1.  Ovarian metastasis from lung adenocarcinoma with ALK-positive rearrangement detected by next generation sequencing: A case report and literatures review.

Authors:  Xuquan Jing; Feng Li; Xue Meng; Zhitong Liu; Jinming Yu; Bo Liu
Journal:  Cancer Biol Ther       Date:  2017-03-31       Impact factor: 4.742

2.  CHALLENGES OF AN OVARIAN NEUROENDOCRINE METASTASIS OF ADVANCED SMALL-CELL LUNG CARCINOMA - LITERATURE REVIEW AND CASE REPORT.

Authors:  V N Varlas; G Angelescu; Y Rhazi; B A Năsui; A L Pop; M L Gheorghiu
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Apr-Jun       Impact factor: 0.877

3.  Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site.

Authors:  Tindara Franchina; Alessandro Russo; Giuseppina Rosaria Ricciardi; Giuseppina Liguori; Astrid Herberg; Nicola Normanno; Vincenzo Adamo
Journal:  Cancer Biol Ther       Date:  2016-09-10       Impact factor: 4.742

4.  Response to crizotinib in a lung adenocarcinoma patient harboring EML4-ALK translocation with adnexal metastasis: A Case Report.

Authors:  Wenxian Wang; Wei Wu; Yiping Zhang
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 5.  Ovarian Metastases from ALK-rearranged Lung Adenocarcinoma: A Case Report and Literature Review.

Authors:  Hajime Sasano; Akimasa Sekine; Toru Hirata; Keisuke Iwamoto; Yuhei Itou; Hidetoshi Itani; Shigeto Kondou; Toshiya Tokui; Motoaki Tanigawa
Journal:  Intern Med       Date:  2018-07-06       Impact factor: 1.271

Review 6.  Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies.

Authors:  Xing Chang; Zi Liu; Shuai Man; Annie Roys; Zengqiang Li; Daiying Zuo; Yingliang Wu
Journal:  RSC Adv       Date:  2019-06-07       Impact factor: 4.036

7.  Ovarian metastases from ALK-positive lung adenocarcinoma: a case report and review of the literature.

Authors:  Huixin Li; Yan Chen; Yingchun Wang; Lin Zhou; Zhongfu Tian; Mengyu Liu; Yang Li; Hanzi Xu; Wangfei Wu; Zhen Gong
Journal:  Transl Cancer Res       Date:  2022-09       Impact factor: 0.496

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.